It is important to appreciate, however, that the increased risk relates to a disorder that is relatively uncommon. NAION is rare, affecting up to 10 out of 100,000 people in the general population
Sales have been robust, with 77% of Vital Pursuit purchases coming from households where no one is using GLP-1 drugs
Personalized Dosing with Precision Peptide Genetic Testing The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R variants that relate to GLP-1 and related signaling pathways
There are no large clinical trials in pregnant women, and animal studies suggest possible risks to the fetus
However, when it is in excess, these benefits are overcome by a pro-inflammatory activity, being associated with worse haemodynamic and metabolic profile in patients affected by HFpEF [35, 36]